Panacea Biotec Limited (IN:PANACEABIO)
:PANACEABIO
Want to see IN:PANACEABIO full AI Analyst Report?
PANACEABIO Stock Chart & Stats
₹358.50
-₹0.60(-0.13%)
At close: 4:00 PM EST
₹358.50
-₹0.60(-0.13%)
Day’s Range― - ―
52-Week Range₹293.10 - ₹581.00
Previous CloseN/A
Volume134.82K
Average Volume (3M)12.44K
Market Cap
₹22.65B
Enterprise Value₹22.30B
Total Cash (Recent Filing)₹1.28B
Total Debt (Recent Filing)₹229.00M
Price to Earnings (P/E)144.8
Beta1.33
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding61,250,744
10 Day Avg. Volume14,140
30 Day Avg. Volume12,438
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)3.31
Price to Sales (P/S)4.94
P/FCF Ratio-35.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Very Low LeveragePanacea's extremely low debt-to-equity (0.03) and high equity ratio (64.73%) provide durable financial flexibility. That capital structure supports multi-month to multi-year funding for R&D, vaccine manufacturing scale-up, or strategic partnerships without immediate debt-service pressure or covenant constraints.
High Gross Profit MarginA ~64% gross margin signals strong control of direct costs and pricing power in core products and vaccines. This margin buffer can sustainably absorb SG&A and R&D investments, enabling longer runway to reach operating profitability if revenue growth and operating efficiencies improve.
Diversified Product And Manufacturing ModelPanacea operates across branded/generics, vaccines, biologics and contract manufacturing with in-house plants and sales/distribution. That diversification reduces single-product concentration risk, supports institutional tenders and export channels, and creates multiple durable revenue vectors.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow undermine the firm's ability to self-fund capex, R&D and working capital. Over a 2-6 month horizon this forces reliance on external financing or equity, constraining strategic investments and raising liquidity risk if losses persist.
Ongoing Operating LossesRecurrent negative EBIT and net losses indicate operating models and cost structure currently fail to deliver profit. Sustained losses erode retained earnings, limit reinvestment capacity, and can delay strategic initiatives until the company generates consistent operating profitability.
Stagnant Revenue And Shrinking Asset BaseStagnant top-line growth combined with declining total assets and shareholders' equity signals limited scale expansion and potential asset erosion. Without renewed revenue momentum, capacity underutilization and weaker balance-sheet metrics can constrain long-term growth and strategic flexibility.
Panacea Biotec Limited News
PANACEABIO FAQ
What was Panacea Biotec Limited’s price range in the past 12 months?
Panacea Biotec Limited lowest stock price was ₹293.10 and its highest was ₹581.00 in the past 12 months.
What is Panacea Biotec Limited’s market cap?
Panacea Biotec Limited’s market cap is ₹22.65B.
When is Panacea Biotec Limited’s upcoming earnings report date?
Panacea Biotec Limited’s upcoming earnings report date is May 28, 2026 which is in 27 days.
How were Panacea Biotec Limited’s earnings last quarter?
Panacea Biotec Limited released its earnings results on Feb 11, 2026. The company reported ₹0.65 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.65.
Is Panacea Biotec Limited overvalued?
According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued.
Does Panacea Biotec Limited pay dividends?
Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on Panacea Biotec Limited dividends here
What is Panacea Biotec Limited’s EPS estimate?
Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panacea Biotec Limited have?
Panacea Biotec Limited has 61,250,744 shares outstanding.
What happened to Panacea Biotec Limited’s price movement after its last earnings report?
Panacea Biotec Limited reported an EPS of ₹0.65 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.399%.
Which hedge fund is a major shareholder of Panacea Biotec Limited?
Currently, no hedge funds are holding shares in IN:PANACEABIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―